Patents by Inventor Jian-Xin Duan

Jian-Xin Duan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of cancer using hypoxia activated prodrugs
    Patent number: 8946275
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: February 3, 2015
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd
  • Treatment of cancer with glufosfamide in patients not receiving insulin therapy
    Patent number: 8765690
    Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: July 1, 2014
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
  • Phosphoramidate Alkylator Prodrugs
    Publication number: 20140170240
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Phosphoramidate alkylator prodrugs
    Patent number: 8664204
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 4, 2014
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS
    Publication number: 20130303778
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 14, 2013
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Camptothecin derivatives
    Patent number: 8575188
    Abstract: Various 14-nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. 14-Nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: November 5, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Xiaohong Cai, Jian-Xin Duan, Mark Matteucci, Yeyu Cao, Hailong Jiao
  • Phosphoramidate alkylator prodrugs for the treatment of cancer
    Patent number: 8552048
    Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: October 8, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
  • Phosphoramidate alkylator prodrugs
    Patent number: 8507464
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 13, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Treatment of Cancer Using Hypoxia Activated Prodrugs
    Publication number: 20130202716
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Application
    Filed: October 21, 2009
    Publication date: August 8, 2013
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd
  • Compositions and methods for treating cancer
    Patent number: 8299088
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: October 30, 2012
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • CAMPTOTHECIN DERIVATIVES
    Publication number: 20120165522
    Abstract: Various 14-Nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. Various 14-nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.
    Type: Application
    Filed: June 16, 2010
    Publication date: June 28, 2012
    Inventors: Xiaohong Cai, Jian-Xin Duan, Mark Matteucci, Yeyu Cao, Hailong Jiao
  • Phosphoramidate Alkylator Prodrugs
    Publication number: 20110251159
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 13, 2011
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Phosphoramidate alkylator prodrugs
    Patent number: 8003625
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 23, 2011
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS FOR THE TREATMENT OF CANCER
    Publication number: 20100183742
    Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.
    Type: Application
    Filed: December 21, 2007
    Publication date: July 22, 2010
    Applicant: Threshold Pharmaceuticals, Inc
    Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS
    Publication number: 20100137254
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered along or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 29, 2006
    Publication date: June 3, 2010
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • GLUFOSFAMIDE COMBINATION THERAPY
    Publication number: 20100104549
    Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.
    Type: Application
    Filed: April 7, 2008
    Publication date: April 29, 2010
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Damian Handisides, Stewart Kroll, Jian-Xin Duan, Harold E. Selick
  • Compositions and Methods for Treating Cancer
    Publication number: 20090312276
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 17, 2009
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Compositions and methods for treating cancer
    Patent number: 7550496
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: June 23, 2009
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
    Publication number: 20090042820
    Abstract: Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.
    Type: Application
    Filed: November 17, 2005
    Publication date: February 12, 2009
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Topoisomerase Inhibitors and Prodrugs
    Publication number: 20080214576
    Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.
    Type: Application
    Filed: November 27, 2005
    Publication date: September 4, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Photon Rao